Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

Resolutions of the Ordinary General Meeting of Shareholders of Basilea 
Pharmaceutica Ltd. 
BASEL, SWITZERLAND -- (Marketwired) -- 04/09/13 --  Basilea
Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved
all agenda items proposed at today's Ordinary General Meeting of
Shareholders for the financial year 2012. At the
meeting, 59.9
percent of Basilea's share capital was represented. 
The shareholders approved the annual report, the financial statements
and consolidated financial statements for the business year 2012, and
discharged the members of the Board of Directors and Management.
Shareholders also approved
carrying forward the accumulated deficit. 
In addition, Dr. Martin Nicklasson was elected to the Board of
Directors for a term of three years. Basilea's Board of Directors now
comprises seven non-executive members: Dr. Martin Nicklasson, Mr.
Hans-Beat Guertler, Prof. Daniel Lew, Dr. Thomas M. Rinderknecht, Mr.
Domenico Scala, Mr. Steven D. Skolsky and
Dr. Thomas Werner. The
Board of Directors elected Dr. Nicklasson as Chairman of the Board
and Domenico Scala as Vice-Chairman. 
The shareholders re-elected PricewaterhouseCoopers AG, Basel, as
Statutory Auditors for the audit of the stand-alone and the
consolidated financial statements for the business year 2013. 
Basilea's shareholders approved the proposal of HBM Healthcare
Investments (Cayman) Ltd., holding 24.97 percent of the company's
shares, to distribute CHF
5.00 per share corresponding to
approximately CHF 48 million from capital contribution reserves to
shareholders. The payment will be made on June 21, 2013. The last
trading day to participate in the distribution will be April 10,
2013. Starting from the ex-date of April 11, 2013, Basilea shares
will
be traded without the right to participate in the distribution. 
In his presentation to shareholders, Chief Executive Officer Ronald
Scott stated: "We achieved significant milestones in 2012 and
successfully focused on our core area of overcoming resistance in
anti-infectives and oncology. The company is uniquely positioned to
potentially create significant value for our
shareholders as we move
closer to the important milestones in the second half of this year:
the potential approval of our antibiotic ceftobiprole in Europe
as
well as the first phase 3 results for our antifungal
isavuconazole." 
The Board and Management expressed their sincere thanks to the
retiring Board
members Werner Henrich, Chairman since the company's
inception, and Claude Schreiner, Board Member since 2007, for their
invaluable contributions. 
Ronald Scott commented: "With his strategic vision, extensive
experience in deal-making and outstanding commitment, Werner Henrich
has passionately worked
as our Chairman to build and grow the company
for more than a decade. Claude
Schreiner's wide-ranging industry
experience was instrumental in creating the
significant value of
Toctino which we were able to achieve for shareholders through our
transaction with Stiefel/GSK last year." 
With the addition of Dr. Nicklasson to the Board, the Board is
convinced that
Basilea is well positioned to continue its path as one
of the leading biopharmaceutical companies addressing the growing
medical need of drug resistance. 
About Basilea 
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland,
and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully
integrated research and
development operations of its Swiss
subsidiary Basilea Pharmaceutica International Ltd., the Company
focuses on innovative pharmaceutical products in the therapeutic
areas of bacterial infections, fungal infections and
oncology,
targeting the medical challenge of rising resistance and
non-response to current
treatment options. 
Disclaimer 
This communication expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance
or achievements of Basilea
Pharmaceutica Ltd. to be materially different from
any future
results, performance or achievements expressed or implied by
such
forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake
to update any forward- looking statements contained herein as a
result of new information, future events or otherwise. 
This press release can be downloaded from www.basilea.com. 
Press release (PDF): http://hugin.info/134390/R/1691712/555610.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE 
[HUG#1691712] 
Media Relations
Peer Nils Schroder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com 
Investor Relations
Barbara Zink, PhD, MBA
Head Corporate Development
+41 61 606 1233
investor_relations@basilea.com
 
 
Press spacebar to pause and continue. Press esc to stop.